Full Breakdown
GSK Acquires Global Rights to Chimagen’s Trispecific T-Cell Engager for Multiple Myeloma
By Drooid · · How we work
Deal Overview
GSK plc announced an agreement to purchase full global rights to a trispecific T-cell engager (TCE) from Chengdu-based biotech Chimagen Biosciences. The transaction is valued at up to US $750 million, comprising an undisclosed upfront payment plus development and commercial milestone payments. The asset is intended for the treatment of multiple myeloma and is slated to enter Phase I clinical trials in 2027.
Background & Context
T-cell engagers are engineered antibody molecules that link a patient’s T cells to cancer cells, prompting an immune attack. Existing TCEs have shown strong efficacy in multiple myeloma but are limited by tolerability concerns. Chimagen’s candidate is designed to bind T cells while simultaneously targeting two validated tumour-associated antigens, a trispecific approach that GSK says could deliver deeper, more durable responses with an improved safety profile.
Multiple myeloma is the third most common blood cancer globally, with approximately 180,000 new cases diagnosed each year. While current therapies can control disease progression, the condition is generally not curable and often becomes refractory to existing treatments, driving demand for novel agents.
Data & Statistics
- Deal value: up to US $750 million (upfront fee plus milestones).
- Clinical timeline: Phase I trial start projected for 2027.
- Market outlook: GSK cites forecasts that the U.S. TCE market for multiple myeloma could exceed $10 billion by 2032.
- Disease burden: ~180,000 new multiple myeloma cases worldwide annually.
Market Reaction
Following the announcement, GSK shares in London traded around 1,858.5 pence on September 15, 2026, reflecting a modest intraday gain. The move came a day after the company reported positive lung-cancer trial data, which had already lifted the stock by roughly 4.6 percent on September 14, 2026.
Analyst Berenberg upgraded its rating on GSK from Hold to Buy and raised its price target to GBP 22.00, citing the added depth to the oncology pipeline. Other houses, including Royal Bank of Canada and Jefferies, maintained consensus Hold ratings with average price targets near GBX 2,064.
Verbatim Quotes
- “Today’s deal secures a promising T cell engager and advances GSK’s leadership goals in blood cancer. The agreement complements our existing portfolio in multiple myeloma, adding a new potential option to address the different needs of patients facing this complex disease.” — Zhenhao Zhou, Chief Executive Officer, Chimagen Biosciences